146 related articles for article (PubMed ID: 18230545)
21. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.
Jones RN; Mendes C; Turner PJ; Masterton R
Diagn Microbiol Infect Dis; 2005 Dec; 53(4):247-56. PubMed ID: 16360548
[TBL] [Abstract][Full Text] [Related]
22. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
Chen MJ; Wang H;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the in vitro activity of 9 antimicrobials against bacterial strains isolated from patients in intensive care units in brazil: MYSTIC Antimicrobial Surveillance Program.
Mendes C; Hsiung A; Kiffer C; Oplustil C; Sinto S; Mimica I; Zoccoli C;
Braz J Infect Dis; 2000 Oct; 4(5):236-44. PubMed ID: 11063555
[TBL] [Abstract][Full Text] [Related]
24. [Antimicrobial resistance of Gram-negative bacilli isolated from 13 teaching hospitals across China].
Wang Q; Zhao CJ; Wang H; Yu YS; Zhu ZH; Chu YZ; Sun ZY; Hu ZD; Xu XL; Liao K; Xu YC; Zhang LY; Mei YN; Yang B; Ni YX
Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1388-96. PubMed ID: 24025503
[TBL] [Abstract][Full Text] [Related]
25. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Burgess DS; Hall RG
Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
[TBL] [Abstract][Full Text] [Related]
26. Prevalence and contributing factors of nonsusceptibility to imipenem or meropenem in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Park YJ; Yu JK; Park KG; Park YG; Lee S; Kim SY; Jeong SH
Diagn Microbiol Infect Dis; 2011 Sep; 71(1):87-9. PubMed ID: 21397426
[TBL] [Abstract][Full Text] [Related]
27. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
[TBL] [Abstract][Full Text] [Related]
28. Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004).
Rhomberg PR; Fritsche TR; Sader HS; Jones RN
J Chemother; 2005 Oct; 17(5):459-69. PubMed ID: 16323433
[TBL] [Abstract][Full Text] [Related]
29. [Evolution of susceptibility to antibiotics of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii, in a University Hospital Center of Beirut between 2005 and 2009].
Hamouche E; Sarkis DK
Pathol Biol (Paris); 2012 Jun; 60(3):e15-20. PubMed ID: 21719212
[TBL] [Abstract][Full Text] [Related]
30. Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007).
Patzer JA; Dzierzanowska D; Turner PJ
J Antimicrob Chemother; 2008 Aug; 62(2):369-75. PubMed ID: 18445575
[TBL] [Abstract][Full Text] [Related]
31. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
[TBL] [Abstract][Full Text] [Related]
32. Resistance surveillance in Italy: four-year results from the MYSTIC program.
Fontana R; Lo Cascio G; Giacobone E; Romero E; Cipriani P; Sessa R; Franchino L
J Chemother; 2002 Aug; 14(4):323-31. PubMed ID: 12420847
[TBL] [Abstract][Full Text] [Related]
33. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
[TBL] [Abstract][Full Text] [Related]
34. Investigation of the antibiotic susceptibility patterns of pathogens causing nosocomial infections.
Yaman A; Tasova Y; Kibar F; Inal AS; Saltoglu N; Buyukcelik O; Kurtaran B; Dundar IH
Saudi Med J; 2004 Oct; 25(10):1403-9. PubMed ID: 15494811
[TBL] [Abstract][Full Text] [Related]
35. Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010.
Fernández-Canigia L; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2012 Oct; 11():29. PubMed ID: 23088592
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997-2003).
Turner PJ
Diagn Microbiol Infect Dis; 2004 Dec; 50(4):291-3. PubMed ID: 15582303
[TBL] [Abstract][Full Text] [Related]
37. MYSTIC program: summary of European data from 1997 to 2000.
Goossens H;
Diagn Microbiol Infect Dis; 2001 Dec; 41(4):183-9. PubMed ID: 11777657
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
[TBL] [Abstract][Full Text] [Related]
39. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
[TBL] [Abstract][Full Text] [Related]
40. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
Jones RN; Kirby JT; Rhomberg PR
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
